US 12,780,682
Application 19/230,353 · Granted Nov 3, 2026
Method of making silver-iron titanate nanoparticles and uses thereof
Estimated expiration
April 16, 2041
14y 150d remaining
- Could not fetch continuity data for application PCTIB2021053178: Resource not found (404)
Earliest effective filing
Apr 16, 2021
+ 20 years
Apr 16, 2041
PTA +0d
Apr 16, 2041
No TD
—
Final
Apr 16, 2041
- Earliest effective filing
- Apr 16, 2021
- + 20 years
- Apr 16, 2041
- PTA +0d
- Apr 16, 2041
- No TD
- —
- Final
- Apr 16, 2041
This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included.
Calculation details
Base term
- Filing date
- June 6, 2025
- Earliest effective filing
- April 16, 2021
- Issue date
- November 3, 2026
- PTA
- 0 days
- Base expiry (before PTA)
- April 16, 2041
April 16, 2021 + 20 years = April 16, 2041
- Divisional of application 17/758,821, filed Jul 14, 2022, issued as US 12,509,360
- National stage entry of application PCTIB2021053178, filed Apr 16, 2021
- National stage entry of application PCTIB2021053178, filed Apr 16, 2021
Terminal disclaimers
Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated
You have the date. Your AI can have the file.
Application 19/230,353 · US 12,780,682
PatentReply compiles the prosecution history behind US 12,780,682: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.
One new published application a month is free. The first compile takes a few minutes.
Strategy and filing changes require your approval.
Permanent link
www.patentreply.ai/tools/patent-expiration/US12780682Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.